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Introduction
Fatigue is the most common, troublesome, and costly side 
effect of many cancer (CA) treatment regimens. Not only 
does it impact patients directly, but it also has significant 
repercussions on both direct and indirect health economic 
outcomes.1 CA treatment-related fatigue (CTRF) is defined 
as a “subjective sense of tiredness” that persists over time, 
interferes with activities of daily living, and is not relieved 
by adequate rest.2,3 The majority of CTRF studies are 
associated with chemotherapy regimens; however, fatigue 
during and after external beam radiation therapy (RT) is 
common, increasing in severity during treatment and persist-
ing after RT has been completed.4 CTRF has been reported 
to be the most distressing symptom reported by patients 
with non-metastatic prostate CA who receive RT with the 
greatest negative impact on daily activity, physical well-being/
function, and relationships with significant others.5 The 
trajectory of CTRF is still being defined. During RT, fatigue 
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AbstrAct
bAckground: Fatigue is a common side effect of cancer (CA) treatment. We used a novel analytical method to identify and validate a specific gene 
cluster that is predictive of fatigue risk in prostate cancer patients (PCP) treated with radiotherapy (RT).
Methods: A total of 44 PCP were categorized into high-fatigue (HF) and low-fatigue (LF) cohorts based on fatigue score change from baseline to RT 
completion. Fold-change differential and Fisher’s linear discriminant analyses (LDA) from 27 subjects with gene expression data at baseline and RT com-
pletion generated a reduced base of most discriminatory genes (learning phase). A nearest-neighbor risk (k-NN) prediction model was developed based on 
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conclusIon: The results suggest that a novel analytical algorithm that incorporates fold-change differential analysis, LDA, and a k-NN may have 
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intensification peaks at midpoint, declines after completion 
of RT,6 and becomes chronic in a subpopulation of patients. 
The pathobiology of CTRF, like other toxicities, is complex 
and is probably attributable to a cascade of events resulting 
in radiation-induced pro-inflammatory cytokine production, 
hypothalamic–pituitary–adrenal (HPA) activation dysfunc-
tion, and neuromuscular function abnormalities.7,8
CTRF, like other regimen-related toxicities, does not 
occur in every patient, but rather in a subpopulation of at-risk 
individuals. In the context of individualizing care, the ability 
to predict CTRF risk has the potential to help guide treat-
ment choices for patients and providers. There have been a 
number of attempts to predict CTRF. For example, one study 
reported that elevated pre-treatment fatigue, anxiety, and a 
specific breast cancer diagnosis (eg, ductal carcinoma in situ, 
invasive lobular carcinoma) predicted CTRF during RT in 
early stage breast cancer.9 Another study found dyspnea, pain, 
lack of appetite, feeling drowsy, feeling sad, and feeling irri-
table to be forecasters of CTRF among hematology–oncology 
patients.10
However, as it becomes increasingly clear that CTRF is 
strongly related to a series of underlying genetically controlled 
biological events, the utility of identifying a group of genes 
that impact patients’ risk of the condition seems compelling. 
We hypothesized that radiation-associated fatigue risk, like 
other regimen-related toxicities, is determined not by a single 
gene, but rather a synergistically functioning group of genes. 
This theory is supported by the finding that clusters of SNPs, 
discovered by Bayesian network analysis, have been reported 
to be associated with CTRF risk in patients being treated with 
cycled chemotherapy for breast and colorectal cancers.11,12 
In the current study, we evaluated an alternative analytical 
method in which genes were identified using a series of hier-
archical filters and nearest-neighbor (NN) analysis to identify 
a group of genes that predicted CTRF in men being irradi-
ated for prostate cancer. This proof-of-concept investigation 
not only demonstrated the utility of the analysis, but also con-
firmed the observation that focal radiation therapy is capable 
of inducing gene expression changes in peripheral white blood 
cell RNA.13
Methods
Patients. This study (NCT00852111) was approved by 
the Institutional Review Board of the National Institutes of 
Health (NIH), Bethesda, Maryland, USA. The study involv-
ing human participants is in compliance with the Declara-
tion of Helsinki. Men who were 18 years or older, diagnosed 
with non-metastatic prostate cancer with or without a his-
tory of prostatectomy, and scheduled to receive EBRT with 
or without concurrent androgen deprivation therapy (ADT), 
were enrolled. Men with progressive disease causing signifi-
cant fatigue, those with psychiatric disease within the past 
five years, uncorrected hypothyroidism and anemia, taking 
sedatives, steroids, and non-steroidal anti-inflammatory 
agents, and those with second malignancies, were 
excluded. Patients were recruited at the Magnuson Clinical 
Research Center, NIH, between May 2009 and September 
2011. Subjects signed written informed consents prior to study 
participation.
Fatigue assessment instruments. Clinical and demo-
graphic data (eg, age, race, stage of prostate cancer, EBRT 
dose, type of EBRT technique used, and laboratory values) 
were obtained from chart review. Questionnaires were com-
pleted at baseline (prior to RT) and at completion of RT (day 
38–42 after EBRT initiation). To avoid extraneous influ-
ences on their responses, subjects completed the question-
naires in an outpatient setting before clinical procedures were 
provided.
The 13-item Functional Assessment of Cancer Therapy–
Fatigue (FACT-F), a frequently used, validated, reliable, 
stand-alone measure of fatigue in cancer therapy with coef-
ficient alphas in the mid-90s, was used.14 FACT-F is scored 
from 0–52, the higher the score, the lower the fatigue symp-
toms. A greater than three-point decrease in the FACT-F 
score is considered to be a minimally important change that 
is clinically relevant.15 To optimize the phenotypic charac-
terization of the study participants, subjects were categorized 
into high-fatigue (HF) or low-fatigue (LF) groups based on 
their change in FACT-F scores from baseline to completion 
of EBRT. HF subjects had a decrease of three or more points 
in FACT-F scores, and those who had less than a three-point 
decrease in FACT-F scores between both time points were 
categorized in the LF group. Depressive symptoms were also 
assessed using the 21-item Hamilton Depression Rating Scale 
(HAM-D), a clinician-administered questionnaire with good 
psychometric properties.16
biological sample collection, rnA extraction, and 
microarray experiments. Peripheral blood (2.5 mL) was 
collected at baseline and on the last day of RT, immedi-
ately after FACT-F was administered, from each subject 
using PAXgeneTM Blood RNA tubes (Qiagen, Frederick, 
Maryland, USA) containing red blood cell lysis buffer and 
a RNA-stabilizing solution and stored at −80 °C until RNA 
extraction. Total RNA was extracted using the PAXgeneTM 
Blood RNA system (Qiagen, Frederick, Maryland, USA) 
according to manufacturer’s instructions. The quantity of 
total RNA was measured by a spectrophotometer at an opti-
cal density of 260 nm. RNA quality was assessed using the 
RNA 6000 Nano LabChip® on a Bioanalyzer Agilent 2100 
(Agilent Technologies, Palo Alto, CA, USA). RNA purifi-
cation, cDNA and cRNA synthesis, amplification, hybrid-
ization, scanning, and data analyses were conducted by 
one laboratory technician following standard protocols as 
previously described.17 Affymetrix microarray chips (HG-
U133 Plus 2.0, Santa Clara, California, USA) were used 
for gene expression analysis. The Affymetrix HG-U133 
Plus 2.0 microarray chip is comprised of 47,000 tran-
scripts, including 38,000 well-characterized human genes. 
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Affymetrix GeneChip Command Console (AGCC, 3.0 V) 
was used to scan the images for data acquisition. Affymetrix 
raw data were acquired using comparison expression analysis 
of GCOS Software to yield CHP files according to the user 
instructions. Peripheral blood has been previously utilized to 
describe gene expression signature that predicted radiation-
related toxicities.18
Ingenuity Pathway analysis (Ingenuity® Systems, www.
ingenuity.com, Redwood City, California, USA) identi-
fied the functional networks of the differentially expressed 
probe sets from Ingenuity’s Knowledge Base. Right-tailed 
Fisher’s exact test was used to calculate the P-values deter-
mining the probability that each biological function and/or 
disease assigned to these networks is due to chance alone. 
The one-tailed analysis was used to reduce the random 
chances of over-representation of focused genes in the rel-
evant pathways.19
statistical rationale. Descriptive analyses were used to 
assess the demographic characteristics of the sample. Paired 
t-tests were used to compare fatigue scores and clinical vari-
ables between time points. To facilitate the identification of a 
group of synergistically functioning genes that were associ-
ated with CTRF risk, we used an approach that optimized 
an initial supervised component with a subsequent statistically 
driven hierarchical ranking. Using microarray data from the 
training set of patients for which the presence or absence of 
CRTF was known, we identified the genes that most discrim-
inated between individuals who developed CTRF from those 
who did not. Those genes were then ranked according to their 
discriminatory value (as defined by their Fisher’s ratio [FR]), 
in which the predictive accuracy of the different-ordered 
reduced sets was determined using a backward recursive fea-
ture elimination algorithm (see flow diagram in Fig. 1 below). 
This procedure serves to eliminate redundant or irrelevant 
genes (features) to yield the most precise set of genes with the 
greatest predictive accuracy.
Feature selection (gene ranking). Feature selection 
identified genes with the highest fold change,20,32 fcj(c1,c2), 
and FR,21FRj(c1,c2), using the phenotype information. The 
fold change and the FR for probe j in a binary classification 
problem are defined as follows:
 
fc j
j
j
c c( , ) log ,1 2 2
1
2
=
µ
µ
 (1)
 
FR j
j j
j j
c c( , ) ,1 2
1 2
2
1
2
2
2
=
−( )
+
µ µ
σ σ
 (2)
where µj1,µj2 are measures of the center of the distribution 
(means) of gene j in classes 1 and 2, and σ σj j12 22,  are measures 
of the dispersion (variance) within these classes.
The following relationship holds:
BLIND Validation
(Reduced Base of Genes)
RFE method
LEARNING DATA SET
Supervised
Feature Selection
(Fold change and Fisher’s ratio)
(LOOCV predictive accuracy &
k-NN classifier)
Shortest Set of Genes +
2D-PCA plot
(k-NN classifier in the
reduced base of genes &
Majority Voting)
Figure 1. Flow diagram for the radiation-related fatigue prediction model. 
The methodology is composed of 4 steps: feature selection, backward 
recursive feature elimination, small-scale separability analysis and blind 
validation.
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where µ µj j1 2−  is the distance between the centers of the 
classes, and σ σ σjT j j= +12 22  is the total variance of the gene 
j in both classes.
The above relationship means that the centers of the dis-
tribution are further apart the distance, k jT.σ . Also, taking 
into account that µ µj jj1 22= ⋅fc , then
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This last relationship implies that given a gene charac-
terized by its FR, FRj, and fold-change value, fcj, only the 
most discriminatory genes with means µj1, µj2 and dispersions 
σj1,σj2 in both classes are selected by this procedure.
Identification/selection of the smallest and most pre-
cise set of ctrF-associated genes. We used the following 
algorithm to select the smallest and most precise set of dis-
criminatory genes for the LF/HF phenotype:
1. Genes identified by feature selection (see above) were 
ranked in decreasing order according to their FR value.
2. The predictive accuracy of the different sets was iteratively 
calculated after the sequential elimination of the genes 
with lowest FR. We termed this novel algorithm, 
a modification of the technique described by Guyon et al 
(2002),22 “backward recursive feature elimination.” It 
served to determine the number of helper genes (genes 
with the lowest FR) needed to maximize the Leave-One-
Out-Cross-Validation (LOOCV) predictive accuracy,23 
in a procedure similar to the Fourier decomposition of a 
signal into a sum of harmonics of increasing frequency.24 
Genes with lower FR provide high frequency details for 
the discrimination. This procedure yielded the shortest 
gene set that predicted fatigue risk association with opti-
mum accuracy (most precise). Other sets with similar and 
lower accuracy were also determined by this procedure 
and were of value, because these sets were also considered 
as noise buffers; as the classifier with the highest learning 
accuracy might not be the one that generalizes (predicts 
correctly unseen samples) better. This approach is appro-
priate and is especially helpful in designing small-scale 
signatures that were able to predict HF/LF with a high 
degree of accuracy.
The linear separability of the phenotype in the reduced 
set of genes that is determined in step 2 was checked by per-
forming principal component analysis (PCA) of the learning 
dataset expressed in this small-scale signature and projecting 
these samples in the corresponding 2D PCA space. Then, the 
LF/HF phenotype becomes linearly separable by reducing the 
dimension to the list of most discriminatory genes, if both 
populations (HF and LF) can be linearly separated by a given 
hyper-plane.
3. The accuracy estimation was based on the LOOCV 
method, using the average Euclidean distance on the 
reduced set of features to each training class set. The 
goal of cross-validation was to estimate how accurately a 
predictive model (classifier) will perform in practice. 
This procedure, applied to the training dataset, is super-
vised because the phenotype information of the patients 
was needed to establish the predictive accuracy of each 
gene list. LOOCV implies using a single sample from 
the original dataset as the validation data (sample test), 
and the remaining samples as training data. This was 
repeated such that each sample in the dataset was used 
once, as a sample test. Each sample was characterized by 
a vector whose dimension was the number of genes that 
belonged to the reduced base that differentiated between 
HF and LF. The class with the minimum Euclidean dis-
tance was assigned to the sample test (NN classifier),25 
and the average accuracy was calculated by iterating 
over all the samples. For that purpose, all the samples 
were normalized according to their gene variability (each 
attribute or gene separately). In this way, all the genes 
had the same importance in the distance criterion. The 
distance between a sample and a phenotype class could 
have been defined in several ways, but the most robust 
one was using the median distance between the sample 
test and all the samples in the corresponding class.
4. The legitimacy of the predictive accuracy based on the 
training set was then tested with the validation set, using 
the above-mentioned predictive model. It is important 
to remark that the application of the prediction model, 
designed in steps 1 to 3, to the validation set was unsu-
pervised. The final decision was made by consensus 
(majority voting) of the predictions made using the lists 
of most discriminatory genes.
results
demographic and clinical characteristics. A total of 
44 men with non-metastatic prostate cancer were studied. 
Subjects were primarily Caucasian (67%), had a mean age of 
65.2 ± 6.7 years and were not depressed based on Hamilton 
Depression Scale (1.1 ± 2.2) criteria. All subjects received a 
cumulative radiation dose of at least 68.4 Gy and more than 
90% received a total dose of 75.6 Gy. Most (64%) of the sub-
jects had a Gleason score of 7–8, and 71% had clinical T-stage 
below T3. The Gleason scoring and clinical staging are unique 
systems to classify the extent of the prostatic carcinoma.26,27 
There was no difference between the clinical and demographic 
features of subjects in the training and validation sets. In gen-
eral, CTRF as indicated by a significant decrease in FACT-F 
scores from baseline (45.4 ± 7.2) to completion of EBRT 
(39.4 ± 10.0, P , 0.05) was found. The characteristics of both 
study sets are shown in Table 1.
training model development. The training model was 
developed from the array outputs of 27 subjects; 18 were HF 
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table 1. Demographic characteristics of the sample.
tRAining vAlidAtion
high FAtiguE
(n = 18)
low FAtiguE
(n = 9)
high FAtiguE
(n = 7)
low FAtiguE
(n = 10)
MEAn (Sd) RAngE n (%) MEAn (Sd) RAngE n (%) MEAn (Sd) RAngE n (%) MEAn (Sd) RAngE n (%)
Age in Years 64.6 (5.7) 53–73 65.2 (7.0) 55–74 66.7 (5.3) 58–73 66.5(7.0) 53–74
Ethnicity n(%)
 Caucasian 18 (100) 7 (78) 2 (29) 5 (50)
 African-American 2 (22) 4 (57) 4 (40)
 other 1 (14) 1 (10)
Clinical T stage 
 T1 (a-c) 4 (22) 2 (22) 2 (29) 2 (20)
 T2 (a-c) 10 (56) 7 (78) 3 (43) 7 (70)
 T3 (a-c) 4 (22) 2 (29) 1 (10)
BMI 30.3 (4.5) 22–37 30.4 (2.7) 26–34 30.4 (6.3) 24–42 31.5 (5.5) 25–40
FACT-F score
 Baseline 43.6 (8.4) 28–52 47.0 (5.6) 36–52 48.9 (5.8) 36–52 42.3 (7.7) 32–51
 Endpoint (day 42) 32.5 (8.1) 20–46 47.4 (4.4) 41–51 39.6 (8.0) 26–48 43.1 (8.1) 31–52
HAM-D score
 Baseline 1.1 (2.2) 0–7 0.6 (0.9) 0–2 0.1 (0.4) 0–1 1.0 (1.3) 0–4
 Endpoint (day 42) 1.8 (2.2) 0–7 0.8 (0.7) 0–2 1.6 (2.2) 0–6 1.6 (1.4) 0–5
Abbreviations: SD, standard deviation; BMI, body mass index; FACT-F, Functional Assessment of Cancer Therapy – Fatigue subscale; HAM-D, Hamilton - 
Depression.
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Figure 2. Data visualization in decibels (log2 of the expression). HF is composed of 18 samples, LF 9 samples and Validation 17 samples. The phenotype 
of the validation samples is not used for learning purposes. The expression varies from 21 to 62.088, that is, a fold change of 11, 53. No filtering is 
performed in the expression data, since the feature selection methods that are used are robust to the presence of outliers. Also, the gene selection is not 
only based on differential expression that might be affected by the presence of noise.
(mean FACT-F change = −11.8 ± 6.8) and 9 were LF (mean 
FACT-F change = 0.8 ± 3.3). Each patient sample contained 
604,258 different probes. The minimum and maximum gene 
expressions were 21 and 62,088, respectively.
As shown in Figure 2, it was impossible to visually dis-
tinguish HF and LF microarray outputs in heat map format 
using decibels as units of measure (log2 of gene expression). 
The similarities between the HF and LF groups in the learning 
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Figure 3. Gene expression histograms in log2 scale for the Low Fatigue and High Fatigue subjects. Slight difference can be observed between them 
around the modes of the histograms (24 to 25).
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Figure 4. Fisher’s ratio curve for the Low Fatigue-High Fatigue phenotype discrimination. Genes with the highest Fisher’s ratio were the most important 
biological eigenvectors for the phenotype discrimination, as it happens, for the Fourier analysis of a digital signal and its decomposition into different 
harmonics. In this case, the Fisher’s ratio curve decreases very steeply, in such that only with the first set of genes (14 to 35 genes in this case) can 
the highest discriminative accuracy of the learning data set, can be achieved. Adding genes with lowest discriminatory power indiscriminately does not 
improve the LOOCV predictive accuracy. The backward RFE method is used to determine the amount of details that is needed.
dataset were confirmed by further histogram analysis of gene 
expression. Figure 3 shows that the corresponding statistical 
distributions of gene expressions in both groups were close to 
lognormal, with the main differences between both pheno-
types occurring around the mode of both histograms (expres-
sions around 24 and 26).
A final list of 575 highly discriminatory genes accord-
ing to expression was noted and defined by the intersection 
between those genes that were differentially expressed (located 
in the 0.05% and 99.5% tails of the fold-change ratio cumu-
lative distribution) and which had a FR higher than 0.25 
(Fig. 4).
Additionally, Figure 5 shows the fold change–FR plot 
for genes in the learning dataset with fold change lower 
than −0.52 and higher than 0.67. These values (of gene 
under- and over-expression) corresponded, respectively, to 
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the 0.05% and 99.5% tails of the fold-change distribution. 
It can be observed that the highest FR was 2.12, and that 
genes with the highest fold change did not coincide with 
those exhibiting the highest FR.
Figure 6 shows the predictive accuracy curve of the 
different gene lists, established using the backward fea-
ture elimination algorithm. The shortest list with the high-
est accuracy (92.6%) was composed by the first 14 genes 
with the highest FR. The lists with the first 15, and 29 to 
35 most discriminatory genes also provide the same maximum 
accuracy. As the data suggest, continuously adding genes with 
lower discriminatory power as defined by their FR failed to 
increase the accuracy of discrimination.
When a histogram was used to assess the first 360 most 
discriminatory genes found by our analysis, we noted a shift of 
the mode of distribution for the LF patients to higher expres-
sions (29–210) with respect to the HF case (26–27), suggesting 
that HF patients show mostly lower expressions of these genes 
that we hypothesized were responsible for this phenotypic dis-
crimination (Fig. 7).
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Figure 6. Leave-One-Out-Cross-Validation (LOOCV) learning predictive accuracy of the first 360 gene sets with the highest discriminatory power. The 
shortest list with the highest accuracy (92.6%) contains only the first 14 genes. Other sets with similar accuracy adding additional helper genes also exist.
Saligan et al
148 CanCer InformatICs 2014:13
0.1
0.09
0.08
0.07
0.06
0.05
0.04
0.03
0.02
0.01
0 5 10 15
LF samples
HF samples
Gene expression (log2)
Histograms after gene selection
R
el
at
iv
e 
fr
eq
u
en
cy
 (
%
)
20 25 30
Figure 7. Histograms (in log2 scale) for the Low Fatigue (LF) and High Fatigue (HF) patients, of the first 360 most discriminatory genes. Compared 
to Figure 3, a higher discrimination in the modes of the LF/HF phenotypes can be observed: the mode of HF samples is shifted to lowest values 
(approximately 64 instead of 512).
Figure 8 shows the PCA plots (unsupervised method) 
of the learning dataset expressed in the base of the most 14 
(Fig. 8A) and 35 (Fig. 8B) discriminatory genes having the 
highest predictive accuracy. The following can be observed:
1. The LF/HF phenotype discrimination became linearly 
separable in these reduced sets of genes, confirming 
the fact that the classification problem simplifies when 
reducing the dimension to the most discriminatory set of 
genes. Both plots have a similar structure.
 The LF samples lie between samples P1A and xrt28A, 
which is genetically close to the region of the HF samples.
2. Also, sample xrt25A, which belongs to the LF category, 
is surrounded by HF samples. This sample might be a 
biological or behavioral outlier.
3. The HF samples lie between samples xrtp2A and 13A. 
Sample xrt20A also seems to mark a transition between 
LF and HF samples toward the west of the plot.
Interpretative phenomenological analysis. Interpre-
tative phenomenological analysis (IPA) revealed that the 
575 highly discriminatory genes were associated with the 
following canonical pathways: B cell development, autoim-
mune thyroid disease signaling, allograft rejection signaling, 
graft-versus-host disease signaling, and Nur77 signaling in T 
lymphocytes. Further, the differentially expressed genes were 
associated with the following functional networks: cancer 
and neurological disease. Additional IPA was performed on 
the 360 most predictive genes (having a learning predictive 
accuracy higher than 81%), a part of the 575 highly discrimi-
natory genes, and it revealed concordance of pathway attribu-
tions observed in the initial IPA. The top canonical pathways 
of the 360 most predictive genes remained to be related to B 
cell development, but it also revealed other focused pathways 
related to T helper cell differentiation and interferon signal-
ing. The top functional networks of the 360 genes remained 
to be related to cancer, followed by neurological disease and 
psychological disorders, suggesting that the most predictive 
genes are related to behavior experienced by cancer patients.
Validation. Seventeen subjects, independent of the 
training set, were used to assess the validity of the learned 
predictive model. Seven were classified as HF (mean FACT-F 
change = −10.6 ± 6.9) and 10 were LF (mean FACT-F 
change = 0.8 ± 2.2) subjects.
The prediction was based on majority voting, as follows:
1. We first considered the most predictive gene cluster, 
a group consisting of the 14 most discriminatory genes 
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deduced from the learning set, and the values of the 
expressions of these genes on both classes (LF and HF) 
represented in the training dataset. The samples of the 
training set expressed in the reduced base and their phe-
notype information were used to define the distance of 
the NN classifier used in this paper.
2. Second, the values of these discriminatory genes in the 
validation samples were read from the validation dataset. 
For each sample of the validation set, its predicted class 
was established using the k-NN algorithm, using the 14 
different most discriminatory reduced sets of genes that 
were defined by the learning dataset. For instance, given 
the base composed by three first genes of the 14-size 
reduced set of genes, the k-NN algorithm calculated the 
distance defined in three-dimensional space between 
each validation sample and the samples of the training 
dataset belonging to each phenotype class. The class 
with the minimum distance was then predicted for the 
validation sample. This was repeated for the 14 different 
reduced bases, which yielded 14 different class predic-
tions for each sample in the validation set.
3. The final estimated class was then made by consensus or 
majority voting classifiers.28 A posterior probability was 
given to the class prediction, defined as the ratio of the 
number of votes assigned to the predicted class and the 
total number of voters. For example, if a validation sample 
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Figure 8. (a) PCA plot for the learning set in the reduced base of the 14 most discriminatory genes. (b) PCA plot for the learning set in the reduced base 
of the 35 most discriminatory genes. A linear separability with a similar structure can be observed in both cases. Low Fatigue samples lie between P1A 
and xrt18A. Xrt25A might be a biological or behavioral outlier. High Fatigue (HF) samples lie between 13A and xrtp2A. Xrt20A marks the HF limit towards 
the west of the plot. Additional data are needed to perfectly delineate this PCA plot.
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were predicted to be HF) and one to the HF (false nega-
tive, patient predicted to be LF). These samples are outliers 
with respect to this classifier, because their expressions in the 
reduced base of genes are closer to the HF and LF groups, 
respectively (Tables 2, 3, and Fig. 9). Interestingly, the 14 
different predictions for these misclassified samples coincide, 
that is, the probability of these samples belonging to their 
predicted class according to the consensus criterion is 1. This 
fact also strengthens the argument that these samples are bio-
logical or behavioral outliers, that is, their class assignment 
based on the change in their FACT-F scores was ambiguous.
discussion
We have described a novel analytical algorithm to predict 
radiation-related fatigue. RT is a highly utilized treatment 
option for many forms of cancer. While it is efficacious in 
many cases, its toxicity profile is significant and common, but 
not ubiquitous. Consequently, the ability to predict toxicities 
of RT has long been of interest. With better understanding 
of the pathobiology of radiation injury, using genomics as 
the basis for toxicity risk prediction has been the focus of 
active research.29 In contrast to the toxicity presented in this 
paper, the primary toxicity phenotypes studied have been 
tissue-centric injuries such as mucositis, dermatitis, and 
pneumonitis and fibrosis.30 And the primary approaches used 
to try to identify predictive relationships between genes or 
SNPs and toxicities have primarily relied on candidate gene or 
genome-wide association analyses. In both cases, the majority 
of investigations have sought to identify one or two genes or 
SNPs associated with the phenotype of interest. The resulting 
lack of consistency of results has been disappointing.31
Our approach differed in that we proposed that the risk 
of a complex disease, such as CTRF, could well be more eas-
ily defined by identifying groups of simultaneously expressed, 
synergistically functioning genes. While this hypothesis is 
supported by studies in which Bayesian network development 
was used to identify SNP clusters predictive of chemotherapy-
related side effects,11–13 we sought to accelerate and simplify 
the analytical process through the use of a novel method in 
which we used a sequence of supervised and learned (unsuper-
vised) “filters” to identify the most predictive cluster of genes 
for CTRF. Our finding that the gene cluster so identified was 
then able to predict CTRF risk with an accuracy of .75% 
suggests that the approach has validity.
The process of selecting the most predictive cluster of 
genes revealed informative considerations. For example, the 
genes with the highest fold change did not coincide with 
those exhibiting the highest FR because the means of both 
distributions were different, hence their tails did not overlap. 
So, in this method we concluded that FR was a better feature 
selection method than fold change. While, in the case of fold-
change analysis, noisy genes are typically penalized by the FR 
selection method because of an increase of their variance; the 
noise might be amplified by the fold-change ratio. Genes with 
table 2. Mean values for the 14 most discriminatory genes.
hF in  
lEARning
lF in  
lEARning
hF in  
vAlidAtion
lF in  
vAlidAtion
114 388 117 401
152 644 143 546
302 1455 326 1569
343 1659 364 1535
185 861 196 841
149 611 127 460
585 128 381 194
243 1182 252 1049
689 111 536 235
160 65 75 126
247 1225 275 1187
223 80 73 171
269 1329 331 1573
1200 281 1083 485
notes: Mean values of the 14 most discriminatory genes in the High Fatigue/
Low Fatigue groups in the learning and the validation phases. Observe the 
coherence in values in both phases. Bold values indicate the highest mean 
expression values in the learning and validation datasets for HF and LF classes.
table 3. Misclassified samples.
S1 (XRt14) S2 (XRt36) S3 (XRt39) S4 (XRt33)
57 129 87 342
78 257 105 492
136 327 201 1354
122 309 183 1514
79 180 125 765
92 126 168 341
42 44 54 946
103 175 184 1045
41 34 49 1430
62 178 258 52
77 234 183 1142
97 286 374 82
146 239 232 1388
162 167 137 2518
notes: Misclassified samples. Expressions for the 14 most discriminatory 
probes. Samples S1, S2 and S3 were predicted to be High Fatigue and S4 to 
be Low Fatigue. The expression values for S1, S2 and S3 were closer to the 
mean expression of the High Fatigue group in the learning phase. Conversely, 
the expression values for S4 is closer to the Low Fatigue group. S1, S2 and 
S3 might define a new group of Low Fatigue with very small expressions 
(lower than the corresponding expressions observed among High Fatigue 
subjects) in this reduced base of 14 genes.
has 12 predictions in the LF class (and two in the HF class), 
the posterior probability to belong to LF will be 12/14.
The application of this algorithm provided 13 successes 
out of 17 validation samples. Three of the four misclassified 
samples belonged to the LF group (false positives, patients 
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the highest FR and fold change have the biggest discrimina-
tory power and are assumed to be involved in the genesis of 
fatigue.
Interestingly, the histogram analysis of the first 360 genes 
that most discriminated between HF and LF subjects was 
informative in that the shift of the mode of distribution 
showed lower expressions of these genes among HF subjects. 
It seems possible that it is this distributional shift that ulti-
mately is responsible for discriminating the fatigue phenotype 
in this population.
We were unable to correctly predict four samples, based 
on our phenotypic approach, since the consensus provides the 
opposite class in all the cases. These classified samples were 
close to the border of separation between both fatigue classes 
(Fig. 8). There are three possibilities: (1) these samples are 
behavioral outliers, (2) the phenotypic approach needs further 
review and improvement, especially dealing with samples that 
are bordering the cut-off scores set for fatigue grouping, and 
(3) possible use of more sophisticated algorithms (black box 
neural networks) to classify the samples may be needed, which 
could run the risk of losing the clarity in the interpretation.
We recognize that this study was limited by its small 
sample size. Nonetheless, the fact that the analysis was suc-
cessful in predicting LF/HF in an unrelated population with 
reasonable accuracy suggests that increasing the number of 
subjects in the training population would likely improve the 
predictive model’s ability. Nevertheless, this analysis confirms 
that it is possible to separate both classes of the LF/HF phe-
notype by reducing the dimension to the most discriminatory 
genes, provided by their FR.
The importance of predicting toxicity or adverse event 
risk associated with cancer treatment regimens cannot be 
understated as the clinical implications in personalizing cancer 
therapy and prospectively attenuating toxicity risk are signifi-
cant. Furthermore, this type of information provides patients 
and their care-givers more specific knowledge upon which to 
make treatment decisions.
conclusion
A novel analytical algorithm introduced in this study that 
incorporates fold-change differential analysis, linear dis-
criminant analysis, and a k-NN can predict radiation-related 
fatigue in men with non-metastatic prostate cancer. Appli-
cability of this novel algorithm to detect other treatment-
related toxicities in other cancer populations would be 
worthwhile to pursue.
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